April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

April 01, 2025

GEM Helps Put T2D in Remission

Researchers highlight evidence-based lifestyle and pharmacologic strategies, including glycemic excursion minimization and tirzepatide, for early glycemic control in adults with type 2 diabetes.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 31, 2025

Cold Plunges: A Cellular Reset?

New research shows that 1 week of daily cold-water immersion enhances autophagy and reduces cell death signals.

Conexiant

March 31, 2025

Hormone Therapy Boosts Semaglutide Weight Loss

At 12 months, women on hormone therapy achieved 16% total body weight loss with semaglutide, compared to 12% in those not using hormone therapy, researchers reported.

Conexiant

March 28, 2025

Mango Intake Linked to Improved Insulin Sensitivity

Fasting insulin levels were significantly lower with mango intake, according to a new study.

Conexiant

March 28, 2025

AID Improves Glucose Control in Type 2 Diabetes, Study Shows

Automated insulin delivery (AID) reduced glycated hemoglobin by 0.9 percentage points in adults with type 2 diabetes, compared to 0.3 points in those who used continuous glucose monitoring methods alone.

Conexiant

March 27, 2025

FDA Approves First Hyperphagia Drug for PWS

FDA approves Vykat XR as first treatment for hyperphagia in patients with Prader-Willi syndrome; decision follows extended review and long-term efficacy data.

Reuters

March 27, 2025

Simplified Tesamorelin Option for HIV Lipodystrophy

EGRIFTA WR™ has received FDA approval for use in adults with HIV and lipodystrophy to reduce excess abdominal fat with once-weekly reconstitution and a lower injection volume.

Conexiant